1
Return

Targeting the immunometabolism interface: A novel strategy for IPF therapy

delete2025-09-10
delete0
PRE
AI
G
Ganggang Li
Y
Yuzhi Huo
X
Xiaochuan Pan
N
Nan Jia
X
Xuanyu Wu
X
Xinhui Wu
F
Fei Wang *
Q
Quanyu Du *
DOI：10.1016/j.pupt.2025.102394delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
• Immunometabolism crosstalk drives IPF progression. • PPARγ and SPP1 are key regulatory genes in IPF. • Targeting Immunometabolism dysfunction offers new therapies. • Metabolic biomarkers aid in IPF diagnosis and treatment. • Future research should bridge basic and clinical IPF studies.

Journal

P
Pulmonary Pharmacology and Therapeutics
IF:
2.8
Papers:
2.1K
Citations:
2.6K

Organization

No organization information available
Cited Papers

Cited Papers

Citing Papers

Citing Papers